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Abstract
Gene therapy with human adenovirus type 5 (Ad5) has been extensively explored
for the treatment of diseases resistant to traditional therapies. Intravenous
administration leads to rapid clearance from blood circulation and high liver
accumulation, which restrict the use of Ad-based vectors in clinical gene therapy
protocols that involve systemic administration. We have previously proposed that
such limitations can be improved by engineering artificial lipid envelopes around Ad
and designed a variety of artificial lipid bilayer envelopes around the viral capsid. In
this study, we sought to explore further opportunities that the artificially enveloped
virus constructs could offer, by designing a previously unreported gene therapy
vector by simultaneous envelopment of Ad and siRNA within the same lipid bilayer.
Such a dual-activity vector can offer efficacious therapy for different genetic
disorders where both turning on and switching off genes would be needed.
Dynamic light scattering, transmission electron microscopy and atomic force
microscopy were used to characterize these vectors. Agarose gel electrophoresis,
Ribo green and dot blot assays showed that siRNA and Ad virions can be
enveloped together within lipid bilayers at high envelopment efficiency. Cellular
uptake and in vitro transfection experiments were carried out to show the feasibility
of combining siRNA-mediated gene silencing with viral gene transfer using these
newly designed dual-activity vectors.
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Introduction
Gene therapy is currently being evaluated for a wide range of genetic disorders
including cancer, cystic fibrosis (CF), Parkinson’s disease (PD), sickle cell anemia,
amyotrophic lateral sclerosis (ALS), etc. Over the last decade, the gene therapy
community has recognized that a general vector for all genetic disorders will be
difficult to discover, hence the gene transfer agent has to be carefully chosen
depending on a number of aspects such as: genetic condition of the disorder,
targeted cell type, required number of treatments (one versus repeat adminis-
tration), and size and nature (secreted versus cellular product) of the gene to be
delivered. In some cases, a rigorous treatment strategy might be also needed which
involves both the overexpression of a functional transgene (gene delivery) in
combination with the simultaneous silencing of the diseased gene (siRNA/shRNA
delivery) whose overexpression may be involved in the pathogenesis.
Oncolytic adenoviruses, which are one of the most widely studied vector in
cancer treatment, replicate selectively in cancer cells and destroy the cells through
cell lysis. An interesting approach to increase the antitumour activity of oncolytic
viruses has been achieved through the use of RNAi. This double targeting
approach has recently become more popular and involved the combined effect of
oncolysis by adenoviruses and siRNA silencing. The existence of a shRNA
expression cassette (for example, against the mutated K-rasV12 oncogene) within
a viral genome has shown to increase the inhibitory effect on tumour growth.
According to Zhang et al. siRNA delivery by an oncolytic virus has many
appealing features in terms of vector development and anti-tumour activity [1].
Zhang et al. showed that co-treatment of A549 cells with ONYX-411 and siKRas,
led to more than 90% of cell death. Furthermore, the combined activities of
siKRas and viral oncolysis produced significant anti-tumour activity in vivo [1].
Another study showed that co-treatment with siRNA increased DNA replication
of oncolytic Ad and, thus enhanced the spread of virus in the tumour
environment [2]. This technology has also been extended to other genes which are
upregulated in cancer [3–5]. Overall, the results of these studies indicate that the
use of oncolytic Ads to deliver tumour-targeted shRNA offers multiple potential
benefits.
We have previously reported that a variety of artificial lipid envelopes can be
engineered around adenoviral capsid in order to alter the vector characteristics
[6–8]. In this study, we aimed to develop a novel dual-activity vector by
envelopment of Ad and siRNA within a single lipid bilayer. We hypothesised that
these vectors can offer efficacious therapy capabilities for complex genetic
disorders where an efficient therapy would require both ‘turning on’
simultaneously with ‘switching off’ of specific genes. This report offers proof of
concept of a dual-activity vector using the b-Gal and luciferase reporter gene
systems.
Dual-Activity Vectors with Ad and SiRNA
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Results
First, the feasibility of gene delivery by Ad with the subsequent gene silencing by
siRNA independently were studied. We tested three different gene silencing
treatment protocols: pre-, co- and post- silencing (Fig. 1) using a viral vector (Ad-
GFP) to transduce cells and a non-viral vector (DOTAP:Chol-siRNA liposome
complexes) for gene silencing. Fluorescence per mg protein as percentage of the
Ad transfected group indicated that ‘pre-silencing’ and ‘co-silencing’ treatment
groups both showed significantly lower GFP expression compared to the Ad
control group (p,0.001 and p,0.01 versus Ad, respectively). Gene knockdown
efficiency by the’ post-silencing’ protocol was lower than ‘pre- or co-silencing’
and there was no statistical difference compared to Ad (p.0.05). Treatment with
siNeg did not result in gene silencing but showed either the same levels of GFP
expression compared to Ad alone or much higher levels of GFP expression
(Fig. 1b).
In addition to the fluorescence intensity data, western blotting was performed
to reveal any differences in protein level (Fig. 1c). A comparison between bands
corresponding to GFP revealed that siGFP-liposome treated cells produced lower
levels of protein in all silencing groups. Very interestingly, according to ‘pre- and
co-silencing’ protocols, siNeg enhanced GFP expression compared to Ad alone as
shown by both western blotting and fluorescence intensity data (p,0.05 versus
Ad).
In order to assure simultaneous delivery of both siRNA and Ad, we attempted
to co-envelope the virus and nucleic acid in a single vector, calling these as ‘dual-
activity vectors’. Co-enveloped Ad and siRNA vectors were prepared using the
lipid film hydration method followed by sonication. We have previously
engineered and fully characterized enveloped Ad in different lipid bilayers [6–8];
and showed the importance of cationic and pH-sensitive nature for artificial
envelopment. Here, we focused on the simultaneous envelopment of Ad and
siRNA within DC-Chol:DOPE lipid bilayers. DC-Chol:DOPE lipid bilayers have
been extensively studied as a cationic pH-sensitive gene delivery system, and
showed promising results in vitro and in vivo [11–13].
DLS measurements showed moderate increase in hydrodynamic diameter, the
enveloped Ad size increased from 189.4 nm to 200.1 nm following inclusion of
siRNA in the vectors (Fig. 2a). Empty liposomes and siRNA encapsulated
liposomes were 174.0 nm and 200.2 nm, respectively. Zeta potential measure-
ments showed that all vectors had positively charged surface potential (Fig. 2a), in
accordance with the characteristics of the lipid molecules used to form the
bilayers.
The structural characteristics of dual-activity vectors were further elucidated by
transmission electron microscopy (TEM) (Fig. 2b) and atomic force microscopy
(AFM) (Fig. 2c). TEM imaging indicated the characteristic electron dense
icosahedron capsid region for naked Ad. When DC-Chol:DOPE was used for
envelopment, the virions appeared to be surrounded by concentric lipid bilayers.
Similar structures were also obtained for co-enveloped Ad-siRNA vectors.
Dual-Activity Vectors with Ad and SiRNA
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Fig. 1. ‘‘on and off’’ gene expression in vitro with Ad-GFP transfection and siGFP silencing. (a)
Schematic representation of two-vector treatment protocols. For the two-vector approach in vitro cell
transfections, there are three methods: pre-, co- and post- silencing. In pre-silencing, cells are treated firstly
Dual-Activity Vectors with Ad and SiRNA
PLOS ONE | DOI:10.1371/journal.pone.0114985 December 12, 2014 4 / 19
Liposomes encapsulating only siRNA did not show vesicular structures similar to
empty liposomes, which we attributed to the formation of lipoplexes between the
positively charged lipid molecules and negatively charged siRNA. Consistent with
our previous AFM imaging of DOTAP:Chol enveloped Ad [6, 8], the AFM
imaging data offered experimental evidence of encapsulation of virions within
liposomes, manifested by the significant height increases observed for DC-
Chol:DOPE enveloped Ad compared to DC-Chol:DOPE liposomes alone or Ad
virions alone. The interaction between Ad and AFM tip indicated that when tip
retracted from Ad surface there were adhesive forces imposed on the tip (S1
Figure). Such forces are determined by the surface properties of Ad. However, we
did not see such interactions when Ad or Ad+siRNA were enveloped by lipid
bilayers. This further indicated that the Ad or Ad+siRNA were fully enveloped by
a lipid bilayer. Moreover, co-envelopment of Ad and siRNA showed no significant
further increase in overall vector dimensions corroborated by both TEM and AFM
imaging.
Following characterization of these novel dual-activity vectors, we aimed to
assess the envelopment efficiency of both Ad and siRNA. Mobility shift and Ribo
green assays were used to detect the free siRNA after simultaneous envelopment of
Ad and siRNA within lipid bilayers. The mobility shift assay was used to separate
free or non-encapsulated siRNA from siRNA which is encapsulated within the
liposome, and ethidium bromide was used to detect RNA molecules. Negatively
charged siRNA migrates through the agarose gel and enveloped siRNA remains in
the well, associated with the liposome. DC-Chol:DOPE liposomes have a net
positive charge so would migrate towards the anode, however their size restricts
entry into the agarose therefore liposomes and enveloped siRNA were retained in
the well. Therefore the mobility shift assay in Fig. 3a indicated that when
compared to free siRNA lane, dual-activity vectors successfully enveloped siRNA
in DC-Chol:DOPE, even in the presence of Ad. Next, in order to quantify the
envelopment efficiency, we used Ribo green assay (Fig. 3b). Free siRNA was used
as a positive control whereas enveloped Ad was used as a negative control. When
dual-activity vectors were incubated with Ribo green solution (before and after
treatment with Triton X-100 in order to disrupt the lipid bilayer), only 10% of
total siRNA included in the dual activity formulation was detected to be free. This
result indicated that the envelopment efficiency was around 90% as determined by
Ribo green assay (Fig. 3b). In order to determine the Ad envelopment efficiency,
ELISA was carried out using anti-hexon antibodies to detect any unenveloped
with siRNAs complexed to DOTAP:Chol liposomes and after 24 h Ads are added to the cells. In co-silencing
protocol, cells are co-incubated with liposome-siRNA complexes and Ad. For post –silencing, cells are treated
with liposome-siRNA complexes 24 h after Ad transfection. Cells are lysed after the last treatment in each
silencing group and analyzed for gene expression. (b) C33-a cells were subjected to Ad-CMV-GFP (108
particles/mL) transfection and DOTAP:Chol liposomes complexed to siRNA (L-siGFP or L-siNeg, at 60 nM
concentration) treatments at different time points as described. The cells were lysed 24 h after the last
treatment and fluorescence per mg protein was measured to plot GFP expression as percentage of Ad
transfected group. (c) Cell lysates were also run on SDS-PAGE electrophoresis and blotted to reveal the
differences in protein levels in each treatment group. * p,0.05, ** p,0.01, *** p,0.001 versus Ad.
doi:10.1371/journal.pone.0114985.g001
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hexon regions on viral capsid (Fig. 3c). When Ad was enveloped, anti-hexon
antibodies did not recognize the hexon regions of the virus particles. When siRNA
was included, the efficiency did not change, and stayed above 90%. In conclusion,
we achieved significantly high envelopment efficiency (above 90%) for both DC-
Chol:DOPE-Ad and DC-Chol:DOPE-Ad+siRNA.
A luciferase expressing human lung carcinoma cell line (A549-luc-C8) was used
to study the dual-activity vectors in vitro. This cell line is stably expressing
Fig. 2. Characterization of co-enveloped Ad-siRNA vectors by DLS, TEM and AFM. The naked Ad, enveloped Ad, co-enveloped Ad-siRNA and
enveloped siRNA are the vectors examined in this study. (a) The mean average diameter (nm), polydispersity index and surface charge (mV) for each vector
were obtained by DLS. (b) Samples were analyzed by TEM imaging. Scale bars represent 100 nm. Red arrows indicate enveloped Ad vectors. (c) Samples
were analyzed by AFM imaging.
doi:10.1371/journal.pone.0114985.g002
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Fig. 3. Envelopment efficiency of Ad and siRNA in dual-activity vectors. The naked Ad, free siRNA, DC-Chol:DOPE enveloped Ad, co-enveloped Ad-
siRNA and enveloped siRNA were prepared. (a) Mobility shift assay was performed in order to detect the amount of free siRNA. (b) siRNA envelopment
efficiency was quantified with Ribo green assay. (c) ELISA was used to quantify the percentage of free Ad. # p,0.05 versus free siRNA, **p,0.01 versus
Ad.
doi:10.1371/journal.pone.0114985.g003
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luciferase gene, therefore we chose siLuc to silence luciferase and Ad-b-Gal to
deliver b-Gal gene. Cells were incubated with the vectors for 3 h and 24 h after
gene silencing was analyzed by luciferase assay. As seen in Fig. 4, percentage of
relative luciferase activity was around 40–50% when cells were transfected by DC-
Chol:DOPE-Ad+siRNA or DC-Chol:DOPE-siRNA. When the same cell lysates
Fig. 4. The biological activity of co-enveloped Ad and siRNA in DC-Chol:DOPE. The naked Ad, DC-
Chol:DOPE enveloped Ad, co-enveloped Ad-siRNA and enveloped siRNA are the vectors examined in this
study. A549-luc-A9 cells were transfected with these vectors and after 24 h, cells were lysed. (a) Luciferase
assay was performed in order to measure the percentage of luciferase expression. (b) b-Gal expression was
assessed by b-Gal assay. * p,0.05 versus Ad.
doi:10.1371/journal.pone.0114985.g004
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were analyzed for b-Gal activity, DC-Chol:DOPE envelopment showed a lower
gene expression profile compared to naked Ad treated cells. Inclusion of siRNA in
the dual-activity vector system did not alter the biological activity of enveloped Ad
vectors, similar levels of b-Gal expression and luciferase silencing were obtained
(Fig. 4). Negative control experiments were performed with a siNeg sequence, and
the results indicated that the presence of siRNA in dual-activity vectors did not
have any effect on the gene delivery capacity of these vectors (S2 Figure).
These novel dual-activity vectors were prepared via lipid-film hydration
method. DC-Chol:DOPE films were hydrated with siRNA and Ad solution
simultaneously. We compared co-enveloped Ad-siRNA vectors with mixing,
complexation and other controls as shown in Fig. 5a. When we treated cells with a
two-vector approach (DC-Col:DOPE-Ad + DC-Chol:DOPE-siRNA vectors),
same levels of luciferase silencing were obtained as with the dual-activity vector,
however a very low b-Gal expression was seen using this two-vector approach
(Fig. 5b,c). This result showed that delivery of genetic instructions with a two-
vector approach could not be effective as dual-activity vectors. Rather than
encapsulating siRNA together with Ad, siRNA was complexed to DC-Chol:DOPE-
Ad vectors, in order to mimic our dual-activity vectors (single-vector approach by
complexation). When A549-luc-C8 cells were treated with these vectors, luciferase
gene silencing was variable among replicates and very low levels of b-Gal gene
expression were obtained, unlike the novel dual-activity vectors (Fig. 5b,c).
Overall, this data suggested that the dual-activity vectors are more effective for
virus and siRNA delivery than other vectors tested in this study.
Finally we studied the cellular uptake of dual-activity vectors in A549 cells. We
treated the cells with different vectors for 3 h and imaged under CLSM (Fig. 6).
Yellow channel was used to detect Ad which was labelled with Cy3 and far-red
channel was used to track the siRNA-AF700 uptake in the cells. DAPI was used for
nuclear staining. As expected, when cells were treated with naked Ad-Cy3, upon
endosomal release, perinuclear co-localization was observed. However when cells
were incubated with DC-Chol:DOPE-Ad-Cy3, the signals were enhanced possibly
due to the aggregation resulted from cationic charges. Viral particles were detected
mainly in the cytoplasmic space, some escaped from endosomes and migrated
towards the perinuclear region. DC-Chol:DOPE-siRNA-AF700 treated cells
showed green fluorescence from cytoplasmic region, as expected. When we co-
enveloped Ad and siRNA within lipid bilayers, similar cellular uptake profile was
obtained as single vectors. These results suggested that there was no interference
between the genetic material transfer capacity and simultaneous envelopment of
Ad and siRNA in DC-Chol:DOPE envelopes.
Discussion
The basis of gene therapy is to alter a disease phenotype by introducing new
genetic instructions into tissues and cells of patients to compensate for abnormal
or missing functions. For several disorders, simultaneous gene transfer and
Dual-Activity Vectors with Ad and SiRNA
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knockdown by delivery of both genes and siRNA within the same cells may work
synergistically to improve therapeutic outcomes. In this study, we attempted to
illustrate the feasibility of combinatory adenoviral gene transfer with siRNA-
mediated gene silencing by engineering dual-activity vectors.
Fig. 5. The comparison of dual-activity vectors with other gene delivery systems. (a) Dual-activity
vectors were compared with different systems in terms of transgene expression and downregulation. (b)
A549-luc-A9 cells were transfected with these vectors and after 24 h, cells were lysed. Luciferase assay was
performed in order to measure the percentage of luciferase expression. (c) b-Gal expression was assessed by
b-Gal assay. * p,0.05 versus naive.
doi:10.1371/journal.pone.0114985.g005
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Cancer gene therapy with simultaneous oncolytic adenovirus delivery or siRNA
have recently gained popularity and there are a few pilot studies already
combining these technologies [14–16]. In vivo studies have shown that such a
dual- activity approach (oncolysis with silencing) can be considered promising for
cancer therapy [1, 2, 17]. However, these studies engineer shRNA within oncolytic
Fig. 6. Cellular uptake profile of dual-activity vectors. Cy3-labelled Ad (161010 p/ml) and Alexa 700-labelled siNeg (1 nmol) were used in the
envelopment process. Cells were incubated with Cy3-Ad, enveloped Cy3-Ad, co-enveloped Cy3-Ad and AF700-siNeg or enveloped AF700-siNeg. After 3 h
in serum free media, cells were fixed and imaged under CLSM. Pseudo-DIC images (bottom right panels) were combined with a AF700 (bottom left panels),
Cy3 (top right panels) and DAPI (top right panels) fluorescence images. Representative images were taken at 10x (scale bars 520 mm) and 40x (scale bars
55 mm).
doi:10.1371/journal.pone.0114985.g006
Dual-Activity Vectors with Ad and SiRNA
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adenovirus genomes and achieve tumour therapy by intratumoural injections.
The artificial adenovirus envelopment technology we have previously developed
[6, 7] offers evasion of the immune system and provides a promising platform for
systemic administration of re-targeted vectors [18]. We have previously reported
that the HepG2 cellular uptake profile of enveloped Ad vectors is independent of
blood coagulation factors in vitro [18]. In vivo studies proved that the
envelopment can reduce hepatocyte transduction and thus improve hepatotoxi-
city profiles. Moreover, it has been shown that pH-sensitive artificial envelopes
can allow triggerable release and endosomal escape of enveloped virions [8]. We
aimed to widen the capabilities of this vector technology by the inclusion of
siRNA nucleic acids to achieve concomitant gene silencing within the same cell
transfected by the enveloped Ad virions.
The feasibility of gene delivery by Ad and the subsequent gene silencing by
siRNA were first studied independently, using different vectors. We transfected
cells with Ad-GFP and then attempted to knockdown the GFP transgene using
liposome:siGFP complexes in three different treatment protocols as shown in
Fig. 1. Fluorescence and western blot data of GFP showed that pre- and co-
silencing exhibited more effective dual- activity compared to the post-silencing
protocol. However, in the co-silencing protocol wider variation was obtained that
could be explained by a possible interaction between Ad viral particles and
liposome:siRNA complexes in the cell culture environment. This interaction may
be responsible for the observed decrease in the levels of both GFP transfection and
silencing activities within the cells. More importantly, combining Ad gene transfer
with siRNA silencing in a two-vector approach as in our pre-, co- or post-
silencing protocols is not practical and prone to irreproducibility, particularly in
relation to clinical translation. To improve this, we developed a novel, dual
activity vector by co-envelopment of Ad and siRNA within pH-sensitive DC-
Chol:DOPE lipid bilayers.
Interestingly, treatment with siNeg showed higher levels of GFP expression
compared to control groups. We hypothesize that the presence of siNeg during
the transcription of the transgene can lead to overexpression of the protein
product. This gene activation effect from siNeg sequences was also demonstrated
in previous studies and has become a highly controversial topic in the RNAi
research field. There are several hypothesis proposed for this unexpected
activation effect [9, 10] such as the activation of noncoding regulatory regions in
gene promoter, imbalance in bidirectional transcription levels or recruitment of
Argonaute to the target gene promoter. Based on these observations, further
systematic work on the role of siNeg in viral transgene activation is warranted.
Variety of materials is under exploration to address the challenges of in vivo
delivery, including polymers, lipids, peptides, dendrimers and carbon nanotubes
[19–21]. Formulation stability, safety and transfection efficiency should be
considered carefully when designing these gene delivery vectors [22, 23]. In our
dual-activity vectors, we co-enveloped Ad and siRNA within lipid bilayers in
order to achieve efficient simultaneous gene transfection and silencing with
improved vector stability. It is well known that encapsulating siRNAs rather than
Dual-Activity Vectors with Ad and SiRNA
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complexation with cationic liposomes is a more promising option to overcome
obstacles such as low stability on serum, inefficient internalization by target cells
and protection from nuclease activities [24, 25]. Furthermore, numerous studies
have reported that incorporation of plasmid DNA into siRNA lipoplexes can form
stable vector systems and enhance the silencing effect of specific genes [26–28].
These reports support the concept of combining Ad and siRNA within the same
lipid bilayer. DLS and TEM/AFM microscopy showed that stable dual-activity
nanoscale vectors with a mean diameter between 100–200 nm could be obtained.
Another study reported that simultaneous gene transduction and silencing can be
achieved by chimeric nanoparticles in which an adeno-associated viral particle was
shielded with an acid-degradable, siRNA-encapsulating polyketal shell [29]. In
this study, in vitro experiments suggested that co-envelopment of Ad and siRNA
within lipid bilayers resulted in biologically functional dual-activity gene therapy
vectors, compared to single vectors alone. We speculate that delivery of two
different vectors to a single cell would happen at a lower frequency and with a
higher variability than using a single vector to co-deliver different genetic material
simultaneously. Alternatively, presence of different liposomal systems (one with
Ad and the other with siRNA) could interfere with each other during cellular
uptake and decrease efficiency. Another reason could be the possible off-target
effect of siRNA on CMV promoter of Ad through NF-kB activation. Further
studies are needed to explain this observation at the molecular level. In this study,
b-gal expression levels of enveloped Ad vectors were lower than the naked virions,
since the pH-sensitive cationic lipid bilayer (DC-Chol:DOPE) used in this study
was not as effective as the previously reported pH-sensitive anionic envelope
DOPE:CHEMS. Therefore future studies could further improve the transfection
efficiency of these dual-activity vectors by changing the characteristics of artificial
lipid bilayers.
Dual-activity vectors offer relatively facile development that does not require
extensive genetic engineering as in the case of other double-targeting vector
systems employing oncolytic Ad with shRNA within the viral genome. Variety of
siRNA sequences can be co-enveloped enhancing the flexibility and multiplicity of
gene targets for such vectors. Additionally, it has been observed that shRNA
delivery via viral vectors is not effective in tumours with low concentration levels
of Dicer which is required for the processing of shRNA [30]. Therefore, co-
envelopment of Ad-siRNA vector bypasses the need for the Dicer, and offers an
advantage to the other dual-activity vector systems to provide a new generation of
multi-functional gene transfer platform.
Materials and Methods
Materials
Recombinant Adenovirus type 5 vectors (Ad-b-Gal and Ad-GFP) were purchased
from the Baylor College of Medicine, Vector Development Laboratory in Texas,
USA. Ad.b-Gal encodes b-Galactosidase and Ad-GFP carries enhanced green
Dual-Activity Vectors with Ad and SiRNA
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fluorescent protein reporter gene under the control of cytomegalovirus (CMV)
promoter. Viral stocks were obtained at a concentration of 561012 particles/ml
(561012 p/ml), which were equivalent to 1.261011 plaque-forming units (pfu)/
ml, in 20 mM HEPES, 150 mM NaCl and 10% glycerol at pH 7.8 and stored at
280 C˚ until ready for use. A549-luc-C8 cell line (Caliper Life Scienves, USA) is a
luciferase expressing cell line derived from A549 by stable transfection of the
North American Firefly Luciferase gene expressed from the CMV promoter.
A549-luc-C8 were maintained in RPMI-1640 and human hepatocarcinoma
HepG2 cells (ATCC, USA) were maintained in Minimum Essential Medium
(MEM), both supplemented with 10% fetal bovine serum (FBS), 50 U/ml
penicillin, 50 mg/ml streptomycin, 1% L-glutamine and 1% non-essential amino
acids at 37 C˚ in 5% CO2. DC-Cholesterol (DC-Chol, 3ß-[N-(N’,N’-dimethyla-
minoethane)-carbamoyl]cholesterol hydrochloride) and DOPE (1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine) lipids were purchased from Avanti Polar Lipids
(Alabama, USA). Bovine serum albumin (BSA) and HRP-labelled anti mouse IgG
were obtained from Sigma, UK. BCA Protein assay kit 1-Step Ultra TMB-ELISA
substrate and ECL detection system were purchased from Fisher, UK. Mouse anti-
hexon antibody (ab8251) was from Abcam plc, UK.
Co-envelopment of Ad and siRNA in lipid bilayers
Dual activity vectors were prepared with lipid film hydration method similar to
artificial envelopment of Ad. In brief, Dc-Chol:DOPE (at 1:3 molar ratio with
3 mM total lipid concentration) were dissolved in 4:1 chloroform: methanol and
lipid films were prepared using a rotovaporator (Buchi, Switzerland). Lipid films
were hydrated with 1 ml of 56109 p/ml Ad- b-Gal and 0.625 nmol siLuc or siNeg
in 20 mM HEPES, 150 mM NaCl buffer at pH 7.2. For TEM and AFM analysis,
lipid films were hydrated with 161010 p/ml Ad- b-Gal and 0.625 nmol siLuc. For
CLSM studies, Cy3-labelled Ad (161010 p/ml) and Alexa 700-labelled siNeg (1
nmol) were used. Following lipid film hydration, co-enveloped vectors were
sonicated in cuphorn sonicator (Sonics, Switzerland) for 10 cycles of 4 min
(15 sec pulse on and 5 sec pulse off) sonication at 20% amplitude. Samples were
left in the fridge for annealing for 2 h.
Nanoparticle sizing and zeta potential measurements by dynamic
light scattering (DLS)
Size and zeta potential analysis of enveloped Ad, enveloped siRNA, empty
liposomes and co-enveloped Ad-siRNA samples were conducted in Zetasizer
Nano ZS (Malvern Instruments, UK). Size was measured in 1 mL cuvettes and
samples were diluted with 20 mM HEPES, 150 mM NaCl buffer at pH 8.0. Zeta
potential was measured in disposable zetasizer cuvettes, and samples were diluted
in distilled water. Three measurements for sizing and five measurements for zeta
potential were taken.
Dual-Activity Vectors with Ad and SiRNA
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Evaluation of Ad envelopment by ELISA
High-bond ELISA plates were overnight coated with 100 ml of Ad, enveloped Ad
or dual-activity vector samples at different concentrations in carbonate/
bicarbonate buffer, pH 9.0 at 4 C˚. Plates were blocked with 1.5% BSA in TBS for
2.5 h. Wells were washed 3 times with TBS. Mouse anti-hexon antibody at a
concentration of 2.5 mg/ml was used as a detection antibody. After 2.5 h
incubation at 37 C˚, wells are washed 3 times with TBS. 100 ml of HRP-linked anti-
mouse IgG at 1:10000 dilution was added to the wells. 1-Step Ultra TMB-ELISA
was used as a detection system. Sulphuric acid (2 M) was added to stop reaction
and absorbance was measured at 450 nm in Fluostar Omega plate reader
(BMGLabtech,UK).
Transmission electron microscopy (TEM)
Vectors were prepared as described above. Samples were concentrated with 30000
molecular weight cut off (MWCO) spin columns and dried onto a gold grid and
stained with 1% aqueous uranyl acetate. Images were obtained using a CM120
BioTwin electron microscope (Philips, USA).
Atomic force microscopy (AFM)
Vectors were prepared as described above. Samples were concentrated five times
with 30000 molecular weight cut off (MWCO) spin columns and 20 ml of a
suspension containing 1011 Ad particles/ml was deposited on the surface of freshly
cleaved mica (Agar Scientific, Essex, UK), and viruses were allowed to adsorb for
15 min. Unbound viruses were removed by washing with filtered dH2O. Samples
were then dried under a nitrogen stream. Imaging was carried out in
TappingMode using a Multimode AFM, E-type scanner, Nanoscope IV controller,
Nanoscope 5.12b control software (all from Veeco, Cambridge, UK), and a silicon
tapping tip (NSG01, NTI-Europe, Apeldoorn, The Netherlands) of 10 nm
curvature radius, mounted on a tapping-mode silicon cantilever with a typical
resonant frequency of 150 kHz and a force constant of 5.5 N/m, to image
565 mm square areas of the mica surface with a resolution of 5126512 pixels and
a scan rate of 1 Hz. All AFM images were performed in air.
Mobility Shift Assay
Agarose gels (1%) were prepared in TBE buffer and ethidium bromide was added
(0.5 mg/ml). Ad, free siRNA, enveloped Ad, enveloped siRNA, co-enveloped Ad-
siRNA and empty liposome samples were analyzed by agarose gel electrophoresis
system (Bio-Rad, UK). Bands on gels were visualized by UV illumination and
imags captured using the Syngene Gel Box (Syngene, UK).
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Ribo green assay
Dual activity vectors were prepared as described above. In order to detect siRNA
envelopment efficiency, 100 ml from each sample, was treated with 0.01% Triton
X-100 and used in a high range assay (20 ng/mL to 1 mg/mL RNA) with the e
Quant-iT RiboGreen RNA assay. Instructions supplied with the kit were followed
and the sample fluorescence was measured using a fluorescence microplate reader
(excitation ,480 nm, emission ,520 nm). Values were normalized with a blank
and percentage of siRNA envelopment was determined.
In vitro experiments
C33-a cells (human cervix carcinoma cell line) were seeded onto 24-well plates
and incubated at 37 C˚, 5% CO2, overnight. Three different treatment groups to
study the activity of two-vector approach were studied: ‘‘pre-silencing’’, ‘‘co-
silencing’’ and ‘‘post-silencing’’ as shown in Fig. 1a. In ‘‘pre-silencing group’’,
cells were first incubated with 100 nM siGFP or siNeg complexed with
DOTAP:Chol (2:1 mM) liposomes in serum free media and the next day, cells
were transfected with Ad-GFP (108 p/mL) for 3 h. In the ‘‘co-silencing group’’,
Ad-GFP and siRNA complexed with liposomes were added together to the wells
and incubated for 3 h. In ‘‘post-silencing’’ group, cells were transfected with Ad-
GFP on the first day and silenced with siGFP complexed with either DOTAP:Chol
liposomes a day after. For the siNeg experiments, only ‘‘pre-silencing’’ treatment
was followed. Gene expression was analyzed via b-Gal assay or western blotting.
For the dual-vector approach, A549-Luc-C8 cells (luciferase expressing human
lung carcinoma cell line) were transfected with DC-Chol:DOPE (1:3, 3 mM) co-
enveloped Ad- b-Gal (56109 p/ml) and siLuc or siNeg (0.625 nmol). After 3 h,
media was replaced with fresh complete media. Gene expression was analyzed via
b-Gal assay and gene silencing was assessed by Luciferase Assay Kit.
Confocal laser scanning microscopy imaging (CLSM) of GFP
expression and cellular uptake studies
Reporter gene activity was assessed with Confocal Laser Scanning Microscopy
(CLSM) for the cells transfected with Ad-GFP. 24 h after transfection, plates were
observed under confocal microscopy, Zeiss LSM 510 Meta laser scanning confocal
microscope, equipped with a 30 mW argon laser, a 1 mW, 543 nm HeNe laser,
and a 5 mW, 633 nm HeNe laser. Samples were analyzed using two channel
confocal laser scanning microscopy to obtain a pseudo-DIC image combined with
a GFP fluorescence image. Representative images were taken at 10x and 40x.
Cellular uptake of co-enveloped Ad siRNA was studied in A549 cells. Cells were
seeded onto glass coverslips. Next day, Cy3-labelled Ad (161010 p/ml) and Alexa
700-labelled siNeg (1 nmol) were used in the envelopment process. Cells were
incubated with Cy3-Ad, enveloped Cy3-Ad, co-enveloped Cy3-Ad and AF700-
siNeg or enveloped AF700-siNeg. After 3 h in serum free media, cells were washed
3 times with PBS and fixed with cold methanol. Coverslips were mounted on glass
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slides and analyzed using four channel confocal laser scanning microscopy to
obtain a pseudo-DIC image combined with fluorescence signals. Representative
images were taken at 10x and 40x.
Analysis of gene silencing by western blotting
Cells lysates were used to determine GFP protein levels by Western blotting. Total
protein concentration was assessed with BCA Protein assay kit. 100 mg protein
was taken from each supernatant and resolved on 12% SDS- polyacrylamide gel
electrophoresis (PAGE) and transferred to Hybond ECL nitrocellulose mem-
branes. After blocking in 5% non-fat dry milk overnight, the blots were incubated
with rabbit polyclonal GFP antibody in 1:5000 dilution. HRP-linked anti-rabbit
IgG at 1:1000 dilution was used as secondary antibody. The specific bands were
detected with ECL detection system at Syngene Gel Box (Synege,UK).
Statistical Analysis
In vitro experiments were performed in triplicates on at least three independent
occasions. In vivo experiments were performed with at least four animals per
group. Statistical analysis was performed by analysis of variance and Tukey’s
pairwise comparison using SPSS software, version 16.0.
Supporting Information
S1 Figure. Deformation analysis of co-enveloped Ad-siRNA vectors by AFM.
The naked Ad, enveloped Ad, co-enveloped Ad-siRNA and enveloped siRNA are
the vectors examined in this study. Samples were analyzed by AFM imaging.
doi:10.1371/journal.pone.0114985.s001 (PDF)
S2 Figure. The effect of siNeg on the gene delivery capacity of dual-activity
vectors. A scrambled siRNA sequence was used in the dual activity vectors. A549-
luc-A9 cells were transfected and after 24 h, cells were lysed. Luciferase assay was
performed in order to measure the (a) luciferase activity and (b) percentage of
luciferase expression.
doi:10.1371/journal.pone.0114985.s002 (PDF)
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